Antibodies and antibody-derived macromolecules have established themselves as the
mainstay in protein-based therapeutic molecules (biologics). Our knowledge of the structure …

Antibody-drug conjugates (ADCs) combine the tumor selectivity of antibodies with the
potency of cytotoxic small molecules thereby constituting antibody-mediated chemotherapy …

Alzheimer's disease (AD) is the most common form of neurodegenerative disease and is
considered the main cause of dementia worldwide. Genome-wide association studies …

Introduction The rationally designed pyrrolobenzodiazepine (PBD) dimers emerged around
ten years ago as a new class of drug component for antibody-drug conjugates (ADC). They …

Neutrophils, the most abundant leukocytes in human blood, are essential fighter immune
cells against microbial infection. Based on the finding that neutrophils can either restrict or …

Simple Summary Relapse after apparent remission remains a major cause of death in
patients with acute myeloid leukemia (AML). On the cellular level, leukemia relapse is …

Introduction: The development and optimization of antibody drug conjugates (ADCs) rely on
improving their analytical and bioanalytical characterization, by assessing critical quality …

The field of chemical modification of proteins has been dominated by random modification of
lysines or more site-specific labeling of cysteines, each with attendant challenges. Recently …

Antibody-drug conjugates offer the possibility of directing powerful cytotoxic agents to a
malignant tumor while sparing normal tissue. The challenge is to select an antibody target …

Passive antibody therapies have a long history of use. In the 19th century, antibodies from
xenographic sources of polyclonal antibodies were used to treat infections (diphtheria). They …